Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel H Greig

Showing results (111-120 of 332) with videos related to

Pageof 34
Sort By:
Chemico-Biological Interactions|May 13, 2008
Flexibility versus "rigidity" of the functional architecture of AChE active centerAvigdor Shafferman, Dov Barak, Dana Stein, et al.
Journal of Neuroinflammation|January 27, 2012
TNF-α protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammationKarim Belarbi, Timothy Jopson, David Tweedie, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
miRNAs: Key Players in Neurodegenerative Disorders and EpilepsyHanuma Kumar Karnati, Manas Kumar Panigrahi, Ravi Kumar Gutti, et al.
Bioorganic & Medicinal Chemistry Letters|October 20, 2022
Thionated aminofluorophthalimides reduce classical markers of cellular inflammation in LPS-challenged RAW 264.7 cellsMichael T Scerba, David Tweedie, Daniela Lecca, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 14, 2012
Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humansMaria L Maccecchini, Mee Young Chang, Catherine Pan, et al.
ACS Pharmacology & Translational Science|February 18, 2022
<i>In Silico</i> and <i>Ex Vivo</i> Analyses of the Inhibitory Action of the Alzheimer Drug Posiphen and Primary Metabolites with Human Acetyl- and Butyrylcholinesterase EnzymesSidra Batool, Tiyyaba Furqan, Muhammad Sibte Hasan Mahmood, et al.
Journal of Neurochemistry|May 19, 2015
Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in miceYazhou Li, Miaad Bader, Ian Tamargo, et al.
Current Drug Targets|February 1, 2003
A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's diseaseDebomoy K Lahiri, Martin R Farlow, Kumar Sambamurti, et al.
Current Alzheimer Research|June 25, 2005
An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's diseaseNigel H Greig, Kumar Sambamurti, Qian-sheng Yu, et al.
Current Alzheimer Research|December 16, 2006
Taking down the unindicted co-conspirators of amyloid beta-peptide-mediated neuronal death: shared gene regulation of BACE1 and APP genes interacting with CREB, Fe65 and YY1 transcription factorsDebomoy K Lahiri, Yuan-Wen Ge, Jack T Rogers, et al.
Pageof 34

Showing results (111-120 of 332) with videos related to

Sort By:
Pageof 34
Chemico-Biological Interactions|May 13, 2008
Flexibility versus "rigidity" of the functional architecture of AChE active centerAvigdor Shafferman, Dov Barak, Dana Stein, et al.
Journal of Neuroinflammation|January 27, 2012
TNF-α protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammationKarim Belarbi, Timothy Jopson, David Tweedie, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
miRNAs: Key Players in Neurodegenerative Disorders and EpilepsyHanuma Kumar Karnati, Manas Kumar Panigrahi, Ravi Kumar Gutti, et al.
Bioorganic & Medicinal Chemistry Letters|October 20, 2022
Thionated aminofluorophthalimides reduce classical markers of cellular inflammation in LPS-challenged RAW 264.7 cellsMichael T Scerba, David Tweedie, Daniela Lecca, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 14, 2012
Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humansMaria L Maccecchini, Mee Young Chang, Catherine Pan, et al.
ACS Pharmacology & Translational Science|February 18, 2022
<i>In Silico</i> and <i>Ex Vivo</i> Analyses of the Inhibitory Action of the Alzheimer Drug Posiphen and Primary Metabolites with Human Acetyl- and Butyrylcholinesterase EnzymesSidra Batool, Tiyyaba Furqan, Muhammad Sibte Hasan Mahmood, et al.
Journal of Neurochemistry|May 19, 2015
Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in miceYazhou Li, Miaad Bader, Ian Tamargo, et al.
Current Drug Targets|February 1, 2003
A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's diseaseDebomoy K Lahiri, Martin R Farlow, Kumar Sambamurti, et al.
Current Alzheimer Research|June 25, 2005
An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's diseaseNigel H Greig, Kumar Sambamurti, Qian-sheng Yu, et al.
Current Alzheimer Research|December 16, 2006
Taking down the unindicted co-conspirators of amyloid beta-peptide-mediated neuronal death: shared gene regulation of BACE1 and APP genes interacting with CREB, Fe65 and YY1 transcription factorsDebomoy K Lahiri, Yuan-Wen Ge, Jack T Rogers, et al.
Pageof 34